Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Increasing evidence has suggested that systemic inflammation along with local brain inflammation can play a significant role in Alzheimer's disease (AD) pathogenesis. Identifying key molecules that regulate the crosstalk between the immune and the CNS can provide potential therapeutic targets. TNF-α is a proinflammatory cytokine implicated in the pathogenesis of systemic inflammatory and neurodegenerative diseases, such as rheumatoid arthritis (RA) and AD. Recent studies have reported that anti-TNF-α therapy or RA itself can modulate AD pathology, although the underlying mechanism is unclear. To investigate the role of peripheral TNF-α as a mediator of RA in the pathogenesis of AD, we generated double-transgenic 5XFAD/Tg197 AD/TNF mice that develop amyloid deposits and inflammatory arthritis induced by human TNF-α (huTNF-α) expression. We found that 5XFAD/Tg197 mice display decreased amyloid deposition, compromised neuronal integrity, and robust brain inflammation characterized by extensive gliosis and elevated blood-derived immune cell populations, including phagocytic macrophages and microglia. To evaluate the contribution of peripheral huTNF-α in the observed brain phenotype, we treated 5XFAD/Tg197 mice systemically with infliximab, an anti-huTNF-α antibody that does not penetrate the blood–brain barrier and prevents arthritis. Peripheral inhibition of huTNF-α increases amyloid deposition, rescues neuronal impairment, and suppresses gliosis and recruitment of blood-derived immune cells, without affecting brain huTNF-α levels. Our data report, for the first time, a distinctive role for peripheral TNF-α in the modulation of the amyloid phenotype in mice by regulating blood-derived and local brain inflammatory cell populations involved in β-amyloid clearance. SIGNIFICANCE STATEMENT Mounting evidence supports the active involvement of systemic inflammation, in addition to local brain inflammation, in Alzheimer's disease (AD) progression. TNF-α is a pluripotent cytokine that has been independently involved in the pathogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD. Here we first demonstrate that manipulation of peripheral TNF-α in the context of arthritis modulates the amyloid phenotype by regulating immune cell trafficking in the mouse brain. Our study suggests that additionally to its local actions in the AD brain, TNF-α can also indirectly modulate amyloid pathology as a regulator of peripheral inflammation. Our findings may have significant implications in the treatment of RA patients with anti-TNF-α drugs and in the potential use of TNF-targeted therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Although -amyloid ( ) aggregation is traditionally accepted to be the primary initiator of the disease, mounting evidence supports the active involvement of neuroinflammation (Heneka et al., 2015; Heppner et al., 2015).”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 10×
“Only female mice were used in the analysis, as 5XFAD females develop the amyloid phenotype 2 months earlier than 5XFAD males (Oakley et al., 2006; Sesele et al., 2013).”
BackgroundMethodInfluentialComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“Furthermore, microglia have been shown to mediate synaptic loss in AD mice (Hong et al., 2016).”
BackgroundImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 3×
“Although neuroinflammation has been established as a prominent feature in AD pathogenesis (Heppner et al., 2015), evidence suggests that systemic inflammation associated with infection, injury, or obesity also contributes to AD progression and local brain inflammatory response (Perry, 2004;…”
BackgroundNew tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 3×
“It has been reported that microglia can respond to circulating cytokines through several routes, including communication with the stimulated endothelium and perivascular macrophages or the circumventricular organs (Calsolaro and Edison, 2016).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“…studies have demonstrated that the relative AD risk is significantly reduced in RA patients receiving nonsteroidal anti-inflammatory drugs (McGeer et al., 1996; Etminan et al., 2003) or anti-TNF- agents (Chou et al., 2016), suggesting that lowering inflammatory response is beneficial for…”
BackgroundMicroglia: new roles for the synaptic stripper
Kettenmann, H., Kirchhoff, F., & Verkhratsky, A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.023 · Cited by 1,173
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Elevated production of proinflammatory molecules, such as TNF- , IL-1 , and IL-6, has been implicated in AD process (Wyss-Coray and Rogers, 2012).”
BackgroundEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749 · cited 2×
“Elevated TNF- levels have been also implicated in neurotoxicity (Perini et al., 2002; Takeuchi et al., 2006) and reflect disease severity (Paganelli et al.”
BackgroundThe role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701 · cited 2×
“…in the treatment of RA patients with anti-TNF- drugs and in the potential use of TNF-targeted therapies for AD. croglia, the brain-resident immune cells, have been shown to accumulate around amyloid plaques and contribute to A clearance (Cameron and Landreth, 2010; Lee and Landreth, 2010).”
BackgroundD'Mello, C., Le, T., & Swain, M. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3567-08.2009 · Cited by 675 · cited 3×
“Moreover, increased CD45-positive monocytes/macrophages have been detected in the brain of mice with inflammatory liver injury or arthritis (D’Mello et al., 2009; Park et al., 2011).”
BackgroundPerry, V. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.01.004 · Cited by 560 · cited 2×
“suggests that systemic inflammation associated with infection, injury, or obesity also contributes to AD progression and local brain inflammatory response (Perry, 2004; O’Banion, 2014; Calsolaro and Edison, 2016).”
BackgroundEtminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
TMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434
Hawkes, C. A., & McLaurin, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805453106 · Cited by 397
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · cited 1×
“Genetic ablation of TNF receptor-1 or administration of TNFinhibitors in AD mice results in attenuation of the amyloid phenotype (He et al., 2007; McAlpine et al., 2009; Shi et al., 2011b; Tweedie et al., 2012; Gabbita et al., 2015), suggesting that inhibition of TNF- signaling confers a protective…”
BackgroundMildner, A., Schlevogt, B., Kierdorf, K., Böttcher, C., Erny, D., Kummer, M. P., Quinn, M., Brück, W., Bechmann, I., Heneka, M. T., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6209-10.2011 · Cited by 351 · cited 2×
“…mouse model resulted in decreased brain infiltration of blood-derived mononuclear cells and increased amyloid deposition (El Khoury et al., 2007), whereas a subsequent study concluded that perivascular macrophages are able to modulate A deposition in a CCR2-dependent manner (Mildner et al., 2011).”
BackgroundJanelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., & Bowers, W. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-23 · Cited by 260
Janelsins, M. C., Mastrangelo, M. A., Park, K. M., Sudol, K. L., Narrow, W. C., Oddo, S., LaFerla, F. M., Callahan, L. M., Federoff, H. J., & Bowers, W. J. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080528 · Cited by 220
Shi, J.-Q., Shen, W., Chen, J., Wang, B.-R., Zhong, L.-L., Zhu, Y.-W., Zhu, H.-Q., Zhang, Q.-Q., Zhang, Y.-D., & Xu, J. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.053 · Cited by 219
Microglial immunophenotype in dementia with Alzheimer’s pathology
CFAS, M., Minett, T., Classey, J., Matthews, F. E., Fahrenhold, M., Taga, M., Brayne, C., Ince, P. G., Nicoll, J. A. R., & Boche, D. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0601-z · Cited by 219 · cited 3×
“, 1996; Greaves and Gordon, 2002) and has been recently implicated in AD (Matsumura et al., 2015; Minett et al., 2016).”
BackgroundTreatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0374-z · Cited by 194 · cited 2×
“RA patients receiving anti-TNF- drugs (infliximab, etanercept, adalimumab) show reduced risk of developing AD (Chou et al., 2016), raising questions about the role of RA and/or antiTNF- therapy in AD.”
BackgroundTobinick, E. (2009) · CNS Drugs · doi:10.2165/11310810-000000000-00000 · Cited by 117 · cited 1×
“Moreover, case studies have reported that treatment of AD patients with the anti-TNF- agents infliximab or etanercept resulted in rapid cognitive improvement (Tobinick and Gross, 2008; Tobinick, 2009; Shi et al., 2011a).”
BackgroundHippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo
Chakrabarty, P., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-16 · Cited by 117
Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease
Masliah, E., Mallory, M., Hansen, L., Alford, M., Albright, T., Terry, R., Shapiro, P., Sundsmo, M., & Saitoh, T. (1991) · Acta Neuropathologica · doi:10.1007/bf00294425 · Cited by 112 · cited 1×
“…microglia and infiltrating leukocytes that are substantially reduced upon peripheral inhibition of huTNF- by infliximab CD45-positive infiltrating leukocytes and periplaque activated microglia have been detected in both human and mouse AD brains (Masliah et al., 1991; Cameron and Landreth, 2010).”
BackgroundAudoy-Rémus, J., Richard, J.-F., Soulet, D., Zhou, H., Kubes, P., & Vallières, L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3510-08.2008 · Cited by 93 · cited 4×
“In mice with endotoxemia, peripheral CD45 monocytes are attracted to the brain vasculature and give rise to perivascular macrophages in response to TNF- , IL-1 , and angiopoietin-2 (Audoy-Rémus et al., 2008).”
BackgroundInfluential
Cited by
Silvin, A., Uderhardt, S., Piot, C., Da Mesquita, S., Yang, K., Geirsdottir, L., Mulder, K., Eyal, D., Liu, Z., Bridlance, C., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.004 · Cited by 368
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
“Systemic treatment with infliximab, an anti-huTNF-α antibody that does not cross the BBB, protects neurons, reduces gliosis, and prevents infiltration of peripheral immune cells without altering brain huTNF-α levels [346,347].”
BackgroundThe Impact of Systemic Inflammation on Alzheimer’s Disease Pathology
Xie, J., Van Hoecke, L., & Vandenbroucke, R. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796867 · Cited by 324
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Metadata
- Authors
- Paouri, E., Tzara, O., Kartalou, G.-I., Zenelak, S., & Georgopoulos, S.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-04-25
- Volume
- 37
- Issue
- 20
- Pages
- 5155-5171
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2609242531
- Cited by
- 76
- References
- 29
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.